Axon Enterprise, Inc. (NASDAQ:AXON) Stock Position Increased by Diversified Trust Co

Diversified Trust Co grew its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 61.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,140 shares of the biotechnology company’s stock after purchasing an additional 813 shares during the period. Diversified Trust Co’s holdings in Axon Enterprise were worth $670,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AXON. ING Groep NV raised its position in shares of Axon Enterprise by 9.3% during the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock worth $2,491,000 after buying an additional 821 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its stake in Axon Enterprise by 18.4% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 104,587 shares of the biotechnology company’s stock valued at $27,019,000 after purchasing an additional 16,230 shares in the last quarter. BKM Wealth Management LLC bought a new position in Axon Enterprise during the 4th quarter valued at $32,000. Apollon Wealth Management LLC bought a new stake in shares of Axon Enterprise in the 4th quarter worth $234,000. Finally, Cim LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at $1,409,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Up 1.2 %

Shares of NASDAQ:AXON opened at $296.56 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. The stock’s 50-day moving average is $294.87 and its 200-day moving average is $285.85. The company has a market cap of $22.38 billion, a P/E ratio of 86.71 and a beta of 0.95. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.95 by $0.20. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The company had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. During the same period in the previous year, the business posted $0.51 EPS. The company’s revenue for the quarter was up 34.3% on a year-over-year basis. Equities research analysts predict that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AXON shares. Morgan Stanley lifted their price objective on shares of Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, April 26th. JMP Securities reiterated a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a research report on Tuesday, May 7th. JPMorgan Chase & Co. lifted their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a report on Thursday, April 11th. Argus initiated coverage on Axon Enterprise in a research note on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price objective for the company. Finally, Barclays upped their target price on Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a report on Wednesday, May 8th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Insider Buying and Selling at Axon Enterprise

In other news, insider Jeffrey C. Kunins sold 43,668 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the completion of the transaction, the insider now owns 189,719 shares of the company’s stock, valued at $58,801,506.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Axon Enterprise news, insider Jeffrey C. Kunins sold 43,668 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $309.94, for a total value of $13,534,459.92. Following the sale, the insider now owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President Joshua Isner sold 44,000 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the transaction, the president now directly owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The disclosure for this sale can be found here. Insiders sold a total of 89,447 shares of company stock valued at $27,684,677 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.